指南与共识肾癌与肾肿瘤

罕见肾癌管理建议:欧洲泌尿外科学会指南

Recommendations for the Management of Rare Kidney Cancers.
指南 / 共识 · Eur Urol · 2017-07-16

欧洲泌尿外科学会肾细胞癌指南小组在系统综述发现罕见肾癌(RKC)治疗证据严重缺乏后,采用非结构化综述结合关键意见领袖意见,提出基于现有数据的管理建议,强调需多中心协作和亚型特异性分析。

要点

  • 系统综述显示罕见肾癌治疗证据缺乏,仅部分亚型有数据支持舒尼替尼或MET抑制剂。
  • 许多RKC患者被排除在研究之外或未按亚型特异性参数分析。
  • 建议基于现有数据提出,但需多中心研究和亚型特异性分析。

核心结论

  • 系统综述显示罕见肾癌治疗证据缺乏,数据仅支持舒尼替尼或MET抑制剂用于某些特定亚型。
  • 尽管需要额外的多中心研究和亚型特异性分析,作者基于现有数据提出了管理建议。

研究设计与样本

  • 欧洲泌尿外科学会肾细胞癌指南小组先进行系统综述,随后进行非结构化综述,检索Pubmed、Medline及欧洲肿瘤内科学会和美国临床肿瘤学会会议摘要,并咨询关键意见领袖和利益相关者。

主要发现

  • 系统综述显示罕见肾癌治疗证据缺乏,数据仅支持舒尼替尼或MET抑制剂用于某些特定亚型。
  • 越来越多的证据表明特定RKC亚型存在可成药通路。
  • 许多RKC患者目前被排除在研究之外或未使用亚型特异性参数进行分析。

关键数值与推荐

  • 数据仅支持舒尼替尼或MET抑制剂用于某些特定亚型。

临床怎么用

  • 作者基于现有数据提出管理建议。
  • 作者认为需要额外的多中心研究和亚型特异性分析。
  • 基于网络的工具促进亚型特异性全球注册和共享转化研究资源,将有助于生成足够数据以制定循证建议。

局限性

  • 系统综述显示罕见肾癌治疗证据缺乏。
  • 每个亚型患者数量少,需要协调的多中心努力来检验假设。
  • 许多RKC患者目前被排除在研究之外或未使用亚型特异性参数进行分析。
  • 需要额外的多中心研究和亚型特异性分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The European Association of Urology Renal Cell Carcinoma Guideline Panel recently conducted a systematic review of treatment options for patients with advanced non-clear-cell renal cell carcinomas (RCCs), which showed a substantial lack of evidence for management recommendations. OBJECTIVE: To improve the outcomes of patients with rare kidney cancers (RKCs), we performed a subsequent unstructured review to determine current treatment strategies and druggable pathways, involving key stakeholders with a global perspective to generate recommendations. EVIDENCE ACQUISITION: Based on the systematic review, literature was queried in Pubmed, Medline, and abstracts from proceedings of European Society for Medical Oncology and American Society of Clinical Oncology, in addition to consulting key opinion leaders and stakeholders. A conventional narrative review strategy was adopted to summarize the data. EVIDENCE SYNTHESIS: The systematic review showed an absence of evidence for treating RKCs, with data only supporting sunitinib or MET inhibitors for some specific subtypes. However, a growing body of evidence implicates druggable pathways in specific RKC subtypes. To test hypotheses, the small patient numbers in each subtype require coordinated multicenter efforts. Many RKC patients are currently excluded from studies or are not analyzed using subtype-specific parameters, despite their unmet medical need. CONCLUSIONS: We recognize the need for additional multicenter studies and subtype-specific analyses; however, we present management recommendations based on the data available. Web-based tools facilitating subtype-specific global registries and shared translational research resources will help generate sufficient data to formulate evidence-based recommendations for guidelines. PATIENT SUMMARY: Patients confronted with rare kidney cancers are often treated the same way as clear-cell renal cell carcinoma patients, despite little evidence from randomized trials. Molecular characterization of tumors to stratify patients may improve outcomes. Availability of potential agents and trials remain a problem. Collaboration among medical centers is important to pool scarce data.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Giles RH, Choueiri TK, Heng DY, et al. Recommendations for the Management of Rare Kidney Cancers. Eur Urol. 2017. PMID: 28720391. doi:10.1016/j.eururo.2017.06.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。